|
[1]
|
COVID-19 clinical and surveillance data — December 9, 2022 to January 30, 2023, China. https://weekly.chinacdc.cn/fileCCDCW/cms/news/info/upload//13642969-aea5-40f9-aa10-165df32c50c0.pdf. [2023-2-2].https://weekly.chinacdc.cn/fileCCDCW/cms/news/info/upload//13642969-aea5-40f9-aa10-165df32c50c0.pdf |
|
[2]
|
Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) 2021 case definition. 2021. https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/. [2022-6-20].https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/ |
|
[3]
|
Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020;5(12):1598 − 607. http://dx.doi.org/10.1038/s41564-020-00813-8CrossRef
|
|
[4]
|
Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020;370(6521):1227 − 30. http://dx.doi.org/10.1126/science.abd7728CrossRef
|
|
[5]
|
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med 2020;383(11):1085 − 7. http://dx.doi.org/10.1056/NEJMc2025179CrossRef
|
|
[6]
|
COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet 2023;401(10379):833 − 42. http://dx.doi.org/10.1016/S0140-6736(22)02465-5CrossRef
|
|
[7]
|
Mao YJ, Wang WW, Ma J, Wu SS, Sun F. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. Chin Med J 2022;135(2):145 − 52. http://dx.doi.org/10.1097/CM9.0000000000001892CrossRef
|
|
[8]
|
Jeffery-Smith A, Rowland TAJ, Patel M, Whitaker H, Iyanger N, Williams SV, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. Lancet Healthy Longevity 2021;2(12):e811 − 9. http://dx.doi.org/10.1016/S2666-7568(21)00253-1CrossRef
|
|
[9]
|
Powell AA, Kirsebom F, Stowe J, Ramsay ME, Lopez-Bernal J, Andrews N, et al. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study. Lancet Infect Dis 2023;23(4):435-44. http://dx.doi.org/10.1016/S1473-3099(22)00729-0.http://dx.doi.org/10.1016/S1473-3099(22)00729-0 |
|
[10]
|
Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic omicron infections. N Engl J Med 2022;387(1):21 − 34. http://dx.doi.org/10.1056/NEJMoa2203965CrossRef
|